Shanghai Junshi Biosciences (HKG:1877, SHA:688180) received a drug registration certificate from China's National Medical Products Administration for a new indication for toripalimab, according to a Hong Kong bourse filing on Thursday.
The pharmaceutical company's Shanghai shares dropped by less than 4%, while Hong Kong shares fell by less than 2% during Friday's morning trade.
The drug, which trades as Tuoyi, will be allowed for the treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma in combination with disitamab vedotin, an antibody drug conjugate developed by RemeGen (HKG:9995, SHA:688331).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments